Relapsed And Refractory Follicular Lymphoma clinical trials

Explore recruiting relapsed and refractory follicular lymphoma clinical trials.

Recruiting relapsed and refractory follicular lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed And Refractory Follicular Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1)

Denmark, Hungary, Slovakia, Sweden, Austria, Greece +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Relapsed And Refractory Follicular Lymphoma trials by city

Relapsed And Refractory Follicular Lymphoma clinical trials

Recruiting relapsed and refractory follicular lymphoma studies right now

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma

Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Also recruiting in Europe

A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1)

Relapsed And Refractory Follicular Lymphoma trials by city

Other conditions